Market Cap 1.13B
Revenue (ttm) 0.00
Net Income (ttm) -122.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 424,000
Avg Vol 790,720
Day's Range N/A - N/A
Shares Out 57.60M
Stochastic %K 15%
Beta -1.89
Analysts Strong Sell
Price Target $76.08

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
ContrarianChamp
ContrarianChamp Aug. 27 at 6:47 AM
$GPCR sitting near support, reaction here will be critical.
0 · Reply
Quantumup
Quantumup Aug. 26 at 4:49 PM
$LLY $NVO $VKTX $GPCR $TERN ZLDPY AMGN RHHBY PFE AZN MRK William Blair: In what we view as yet another surprising development, orforglipron outperformed investor expectations in patients living with both overweight/obesity and type 2 diabetes, which we view as the higher-risk and more difficult-to-treat population. Based on contemporary epidemiology, roughly a quarter of overweight/obese individuals also have type 2 diabetes. Accounting for the three Phase III studies of orforglipron, we believe the franchise exhibited the highest competitive advantage in diabetes (roughly 15% of the U.S. adult population). Furthermore, patients living with type 2 diabetes often have comorbid conditions (such as hypertension or dyslipidemia), which are most commonly managed with oral medications. It is therefore our opinion that orforglipron could be seamlessly incorporated into patients' daily routines, thereby encouraging uptake.
0 · Reply
biolover
biolover Aug. 26 at 1:52 PM
$VKTX volume 1.5 m in 15 mints vs 15 k in $GPCR that should react more to $LLY news ? Something mysterious.
0 · Reply
biolover
biolover Aug. 22 at 10:47 PM
$VKTX Reminder $GPCR oral GLP1 agonist ( replica of $LLY orfoglipron) got 6-7% wt loss at 12 wks in phase 2a despite rapid escalation and with 60% Vomiting and with no placebo effect .. $PFE Danu with rapid escalation resulted in 3.7% wt loss at 12 wks with 45% vomiting Just to place them all in comparison to $VKTX oral VK2735 …
0 · Reply
DAR2487
DAR2487 Aug. 21 at 10:41 PM
$GPCR sure seems like alot of buyers have been getting in. This will likely grind up to mid 20s before news sends this back to 50+
0 · Reply
PrnceMichael
PrnceMichael Aug. 21 at 4:15 PM
$PFSA Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform $GPCR $PFSA $VKTX https://www.benzinga.com/pressreleases/25/08/ab47180683/profusa-inc-nasdaq-pfsa-establishes-a-distributor-partner-in-spain-for-lumee-oxygen-platform?utm_source=articleShare via @Benzinga @MrSamuelPowers @ProfusaInc @Nasdaq
0 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply
Quantumup
Quantumup Aug. 20 at 3:24 PM
Mizuho reit'd $TERN Outperform/$14: Yesterday, Viking Therapeutics ( $VKTX, NC) announced 13-week P2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity. Though the study hit on the primary endpoint of weight loss for each dose tested, $VKTX shares closed -42% (vs. -2% XBI). Disappointment, we believe, was based primarily on '2735's tolerability profile, which included very high rates of vomiting at the highest doses, and high discontinuation rates. Bigger picture, $VKTX's data for '2735 marks a second consecutive set of disappointing data for an oral GLP-1-based candidate for obesity (following recently reported data for Eli Lilly's ( $LLY, NC) orforglipron). Though questions may emerge on (1) the competitive profiles of oral GLP-1's vs. injectable GLP-1's and (2) their potential positioning in the market, we continue to see an opportunity for TERN-601, for which key P2 data (expected in 4Q25) could show $TERN's oral GLP-1 to be differentiated, particularly on tolerability. $GPCR
0 · Reply
Quantumup
Quantumup Aug. 20 at 11:17 AM
Raymond James Doubles Down on $VKTX (SB-$122) after Y'day's First Look Note and said that it's becoming convinced that not only is '2735 competitive, but c/b the best oral incretin w/@ least 12wks of pbo-controlled data currently in clinical development. $LLY $NVO $GPCR $RHHBY Raymond James in its note to investors said:
0 · Reply
Latest News on GPCR
Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 5 months ago

Structure Therapeutics CEO on latest GLP-1 developments


Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 5 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER


Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs


Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 8:04 AM EST - 1 year ago

Structure Therapeutics stock plunges on new GLP-1 drug data


Final Trades: Rivian, Pfizer, Treasury Bonds and more

Sep 29, 2023, 6:26 PM EDT - 2 years ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT


Structure Therapeutics Appoints Ted W. Love, M.D.

Aug 3, 2023, 5:32 PM EDT - 2 years ago

Structure Therapeutics Appoints Ted W. Love, M.D.


ContrarianChamp
ContrarianChamp Aug. 27 at 6:47 AM
$GPCR sitting near support, reaction here will be critical.
0 · Reply
Quantumup
Quantumup Aug. 26 at 4:49 PM
$LLY $NVO $VKTX $GPCR $TERN ZLDPY AMGN RHHBY PFE AZN MRK William Blair: In what we view as yet another surprising development, orforglipron outperformed investor expectations in patients living with both overweight/obesity and type 2 diabetes, which we view as the higher-risk and more difficult-to-treat population. Based on contemporary epidemiology, roughly a quarter of overweight/obese individuals also have type 2 diabetes. Accounting for the three Phase III studies of orforglipron, we believe the franchise exhibited the highest competitive advantage in diabetes (roughly 15% of the U.S. adult population). Furthermore, patients living with type 2 diabetes often have comorbid conditions (such as hypertension or dyslipidemia), which are most commonly managed with oral medications. It is therefore our opinion that orforglipron could be seamlessly incorporated into patients' daily routines, thereby encouraging uptake.
0 · Reply
biolover
biolover Aug. 26 at 1:52 PM
$VKTX volume 1.5 m in 15 mints vs 15 k in $GPCR that should react more to $LLY news ? Something mysterious.
0 · Reply
biolover
biolover Aug. 22 at 10:47 PM
$VKTX Reminder $GPCR oral GLP1 agonist ( replica of $LLY orfoglipron) got 6-7% wt loss at 12 wks in phase 2a despite rapid escalation and with 60% Vomiting and with no placebo effect .. $PFE Danu with rapid escalation resulted in 3.7% wt loss at 12 wks with 45% vomiting Just to place them all in comparison to $VKTX oral VK2735 …
0 · Reply
DAR2487
DAR2487 Aug. 21 at 10:41 PM
$GPCR sure seems like alot of buyers have been getting in. This will likely grind up to mid 20s before news sends this back to 50+
0 · Reply
PrnceMichael
PrnceMichael Aug. 21 at 4:15 PM
$PFSA Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform $GPCR $PFSA $VKTX https://www.benzinga.com/pressreleases/25/08/ab47180683/profusa-inc-nasdaq-pfsa-establishes-a-distributor-partner-in-spain-for-lumee-oxygen-platform?utm_source=articleShare via @Benzinga @MrSamuelPowers @ProfusaInc @Nasdaq
0 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply
Quantumup
Quantumup Aug. 20 at 3:24 PM
Mizuho reit'd $TERN Outperform/$14: Yesterday, Viking Therapeutics ( $VKTX, NC) announced 13-week P2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity. Though the study hit on the primary endpoint of weight loss for each dose tested, $VKTX shares closed -42% (vs. -2% XBI). Disappointment, we believe, was based primarily on '2735's tolerability profile, which included very high rates of vomiting at the highest doses, and high discontinuation rates. Bigger picture, $VKTX's data for '2735 marks a second consecutive set of disappointing data for an oral GLP-1-based candidate for obesity (following recently reported data for Eli Lilly's ( $LLY, NC) orforglipron). Though questions may emerge on (1) the competitive profiles of oral GLP-1's vs. injectable GLP-1's and (2) their potential positioning in the market, we continue to see an opportunity for TERN-601, for which key P2 data (expected in 4Q25) could show $TERN's oral GLP-1 to be differentiated, particularly on tolerability. $GPCR
0 · Reply
Quantumup
Quantumup Aug. 20 at 11:17 AM
Raymond James Doubles Down on $VKTX (SB-$122) after Y'day's First Look Note and said that it's becoming convinced that not only is '2735 competitive, but c/b the best oral incretin w/@ least 12wks of pbo-controlled data currently in clinical development. $LLY $NVO $GPCR $RHHBY Raymond James in its note to investors said:
0 · Reply
dsdnase
dsdnase Aug. 20 at 10:45 AM
$GPCR Structure is very astute in splitting its phase 2 into 2 studies, one for 120mg, and one for 240+. Even if their higher doses show unacceptable levels of side effects, it would not affect the perception of the 120mg study.
0 · Reply
gazza75799
gazza75799 Aug. 19 at 7:37 PM
$GPCR don't buy volume is lacking with this equity
0 · Reply
BiotechBonesaw
BiotechBonesaw Aug. 19 at 7:22 PM
$VKTX it’s not too late. Sell your shares in Viking and buy $ALT & $GPCR 👍
0 · Reply
bginvest
bginvest Aug. 19 at 6:53 PM
$GPCR $LLY $NVO $TERN $VKTX you’ve to understand we’ve 3 diabetes companies in Denmark with the big brother Novo Nordisk, and then Zealand Pharma in the middle, and the little sister Gubra with a value of 1 billion dollars and just made a deal to several billion dollars and paid 60kr in dividend last month after the deal right now they’re being holding down together with huge value in all 3 and a future 🤯🤷‍♂️
0 · Reply
bginvest
bginvest Aug. 19 at 6:35 PM
$GPCR $LLY $NVO $TERN $VKTX this is stupid just look at their biggest competitor in the same league Zealand Pharma also from Denmark they’ve 2,5 billion dollars in cash after they made a deal earlier this year with a value up to 5,3 billion dollars upfront B4 royalties from the product and they only have a valuation of 4 billion dollars 🧐🤷‍♂️
0 · Reply
Quantumup
Quantumup Aug. 19 at 6:01 PM
Jefferies reiterated $VKTX Buy-$101 and said, we think the market is overreacting on GI AE/ discontinuation profile, underappreciating that it could be modulated by dosing optimization. $LLY $NVO $GPCR $TERN AZN AMGN PFE Jefferies said in its note to investors: We think the market is overreacting on GI AE/ discontinuation profile, underappreciating that it could be modulated by dosing optimization ("start low, go slow" strategy) & oral VK2735 demonstrated robust efficacy, including superior weight loss at upper dose, clinically meaningful/ competitive WL at mid-doses, and good maintenance pot'l even at low doses, all supporting next steps for oral induction Ph2b and oral maintenance studies.
1 · Reply
Quantumup
Quantumup Aug. 19 at 4:43 PM
Stifel reit'd $VKTX Buy-$95 and said it reiterates its Buy following what they think is an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome, where VK2735 still stands out as the most potent & flexible peptide among current contenders. $LLY $NVO $GPCR $TERN Stifel said in its note:
0 · Reply
Quantumup
Quantumup Aug. 19 at 3:41 PM
BTIG reiterated $VKTX Buy/$125. $LLY $NVO $GPCR $TERN AZN AMGN PFE BTIG said in its note to investors: $VKTX is trading down ~40%, and we believe the selloff reflects near-term concerns around tolerability and discontinuation rates in higher doses and competitive positioning in the obesity class. While the safety/tolerability profile was not as clean as in Ph1, as perhaps expected at higher dose levels, we view oral VK2735 data as competitive among the leading oral obesity agents in development. We expect Viking will explore less aggressive titration schedules in further studies to improve the tolerability profile. At 13 weeks, weight loss is highly compelling (pbo-adjusted 11%, 10%, 7.4% for 120, 90, 60mg doses), which we see as competitive to Novo's (NVO, Not Rated) oral armycretin and more effective than Lilly's (LLY, Not Rated) orfoglipiron at similar time-points (see note). Overall, we believe oral VK2735's profile remains commercially competitive. Reiterate Buy rating and $125 PT.
0 · Reply
Quantumup
Quantumup Aug. 19 at 2:06 PM
Truist reiterated $VKTX Buy-$75. $NVO $LLY $GPCR $TERN AMGN PFE AZN Truist said in its note:
0 · Reply
LabPsycho
LabPsycho Aug. 19 at 1:55 PM
$GPCR IMO, No greater red flag to me when I see that a company with $700M decides to do a mixed shelf offering of another ~$200M, near all time lows the past few year, and BEFORE clinical updates. Wealth transfer vehicle - from your hard earned $$$ to insiders - yay. Greed is never satisfied.
0 · Reply
Jabed206
Jabed206 Aug. 19 at 1:39 PM
$GPCR 35,000 watchers on Viking vs 1,300 on here lol
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 19 at 1:31 PM
"be fearful when others are greedy and to be greedy only when others are fearful.” $ALT $GPCR $VKTX $MTSR
0 · Reply